The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Oncology & Cancer

Gut bacteria ‘fingerprint’ predicts radiotherapy side effects
Oncology & Cancer

Gut bacteria ‘fingerprint’ predicts radiotherapy side effects

OCT 9, 2019
Bacteria on tumors influences immune response and survival of patients with pancreatic cancer
Oncology & Cancer

Bacteria on tumors influences immune response and survival of patients with pancreatic cancer

AUG 12, 2019
Precision editing of gut bacteria reduces cancer in mice
Basic & Discovery Research

Precision editing of gut bacteria reduces cancer in mice

AUG 7, 2019
5-minute Microbiome Science Roundup: April 2019
Editor's Choice

5-minute Microbiome Science Roundup: April 2019

MAY 4, 2019
4D Pharma Clinical Update on MRx0518 Oncology Programmes
Clinical & Manufacturing

4D Pharma Clinical Update on MRx0518 Oncology Programmes

MAY 1, 2019
Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program
Oncology & Cancer

Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program

APR 17, 2019
Viome and Helomics Partner to Identify Personalized Treatment for Ovarian Cancer Patients
Oncology & Cancer

Viome and Helomics Partner to Identify Personalized Treatment for Ovarian Cancer Patients

MAR 27, 2019
Enterome Announces Research Collaboration with Dana-Farber Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy
Oncology & Cancer

Enterome Announces Research Collaboration with Dana-Farber Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy

MAR 22, 2019
Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca
Finance

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca

MAR 11, 2019
Publication of Data in Connection with 4D Pharma’s Immuno-Stimulant and Anti-Tumour Agent MRx0518
Basic & Discovery Research

Publication of Data in Connection with 4D Pharma’s Immuno-Stimulant and Anti-Tumour Agent MRx0518

FEB 3, 2019
4D pharma & MD Anderson Cancer Center to Evaluate LBPs in Solid Tumours
Oncology & Cancer

4D pharma & MD Anderson Cancer Center to Evaluate LBPs in Solid Tumours

JAN 8, 2019